RxDoctor Payments Data

Jennifer Parrotte, NP

Critical Care Medicine · Wilmington, NCNPI 1164775888

Payments from drug & device makers

$542in general payments, 2019–2025

Across 17 payments — averaging $31.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$207
  • Nxstage Medical, Inc.$136
  • Calliditas Therapeutics US Inc.$62
  • Baxter Healthcare$40
  • Bayer$24
  • Daiichi Sankyo Inc.$22
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$542100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$542 in reported general payments places this provider in the 60th percentile of 190 critical care medicine providers in North Carolina.

See all critical care medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$89,610
Medicare patients
460
Services billed
4,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$75,184
FarxigaDapagliflozin Propanediol96$74,226
Calcium Acetate40$3,603
SpsSodium Polystyrene Sulfon/Sorb31$2,714
ProsolParenteral Amino Acid 20% No.114$2,686
Calcitriol116$1,139
Midodrine Hcl17$1,107
Hydralazine Hcl49$1,105
Sevelamer Carbonate11$1,076
Eplerenone15$1,056
Amlodipine Besylate79$739
Valsartan16$645
Furosemide113$519
Metoprolol Succinate29$493
Gabapentin29$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$207$74,22696 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 190 critical care medicine providers in North Carolina.

Other critical care medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →